Drug-eluting stents and their additional benefit to low-risk patients were investigated in a cost-effectiveness analysis presented to the Stockholm cardiology meeting by Matthias Pfisterer from Basel. Audio Medica talked with him.
[audio:https://www.audiomedica.com/podcasting/14.Matt_Pfisterer-Drug-eluting_stents_may_confer_so_little_additional_benefit_to_low_risk_patients.mp3]
Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...
Atrial fibrillation is prevented by exercise and life-long endurance athletes do not face the same elevated risks of stroke and heart disease from...
AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a...
AMSTERDAM — The SAVOR-TIMI 53 study in 16 000 patients has confirmed the efficacy of the DPP-4 inhibitor, saxagliptin, for controlling glycaemia in...
AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a...
AudioMedica News Young adults less likely to be diagnosed with hypertension than over 60s Play Episode Pause Episode Mute/Unmute Episode Rewind 10...
